NO3140287T3 - - Google Patents

Info

Publication number
NO3140287T3
NO3140287T3 NO15725827A NO15725827A NO3140287T3 NO 3140287 T3 NO3140287 T3 NO 3140287T3 NO 15725827 A NO15725827 A NO 15725827A NO 15725827 A NO15725827 A NO 15725827A NO 3140287 T3 NO3140287 T3 NO 3140287T3
Authority
NO
Norway
Application number
NO15725827A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3140287T3 publication Critical patent/NO3140287T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO15725827A 2014-05-06 2015-05-06 NO3140287T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1454081A FR3020810B1 (fr) 2014-05-06 2014-05-06 Nouveau sel de l'ivabradine et son procede de preparation.
PCT/FR2015/051201 WO2015170053A1 (fr) 2014-05-06 2015-05-06 Nouveau sel de l'ivabradine et son procédé de préparation

Publications (1)

Publication Number Publication Date
NO3140287T3 true NO3140287T3 (pl) 2018-08-04

Family

ID=51518916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15725827A NO3140287T3 (pl) 2014-05-06 2015-05-06

Country Status (21)

Country Link
US (1) US9856221B2 (pl)
EP (1) EP3140287B1 (pl)
JP (1) JP2017514848A (pl)
CN (1) CN106458915B (pl)
AU (1) AU2015257518B2 (pl)
CA (1) CA2947475C (pl)
CY (1) CY1120402T1 (pl)
DK (1) DK3140287T3 (pl)
ES (1) ES2672927T3 (pl)
FR (1) FR3020810B1 (pl)
HR (1) HRP20180716T1 (pl)
HU (1) HUE037755T2 (pl)
LT (1) LT3140287T (pl)
MA (1) MA39756B1 (pl)
ME (1) ME03062B (pl)
NO (1) NO3140287T3 (pl)
PL (1) PL3140287T3 (pl)
PT (1) PT3140287T (pl)
RS (1) RS57147B1 (pl)
SI (1) SI3140287T1 (pl)
WO (1) WO2015170053A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110768A1 (es) 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI832053A7 (fi) * 1982-06-10 1983-12-11 Syntex Inc LHRH-antagonistina käyttökelpoinen LHRH:n nonapeptidi- ja dekapeptidianalogit sekä niiden valmistusmenetevalmistusmenetelmä.
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
NZ563417A (en) * 2005-05-18 2012-01-12 Mpex Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
WO2007064845A1 (en) * 2005-11-29 2007-06-07 Pr Pharmaceuticals, Inc. Sustained release butorphanol drug delivery compositions for analgesia
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8653106B2 (en) * 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2012000061A (es) * 2009-06-24 2012-06-01 Msd Oss Bv Formulaciones inyectables que contienen asenapina, y metodo de tratamiento usando las mismas.
WO2011104723A2 (en) * 2010-02-23 2011-09-01 Ind-Swift Laboratories Limited Acid addition salts of ivabradine and preparation thereof
WO2011157721A2 (en) * 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US9040695B2 (en) * 2011-04-26 2015-05-26 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects

Also Published As

Publication number Publication date
CA2947475C (fr) 2018-07-10
JP2017514848A (ja) 2017-06-08
PT3140287T (pt) 2018-03-22
FR3020810B1 (fr) 2016-05-06
FR3020810A1 (fr) 2015-11-13
CY1120402T1 (el) 2019-07-10
ME03062B (me) 2019-01-20
EP3140287B1 (fr) 2018-03-07
DK3140287T3 (en) 2018-06-14
ES2672927T3 (es) 2018-06-18
AU2015257518B2 (en) 2018-12-13
CN106458915B (zh) 2019-05-07
HUE037755T2 (hu) 2018-09-28
AU2015257518A1 (en) 2016-11-03
EP3140287A1 (fr) 2017-03-15
MA39756B1 (fr) 2018-05-31
SI3140287T1 (en) 2018-05-31
US20170050932A1 (en) 2017-02-23
LT3140287T (lt) 2018-04-10
HRP20180716T1 (hr) 2018-06-15
MA39756A (fr) 2018-03-07
CA2947475A1 (fr) 2015-11-12
CN106458915A (zh) 2017-02-22
PL3140287T3 (pl) 2018-07-31
RS57147B1 (sr) 2018-07-31
US9856221B2 (en) 2018-01-02
WO2015170053A1 (fr) 2015-11-12

Similar Documents

Publication Publication Date Title
BR112016017664A2 (pl)
BR112016017979A2 (pl)
BR112016015519A2 (pl)
BR112016015890A2 (pl)
BR112016016490A2 (pl)
BR112016003131A2 (pl)
BR112016027628A2 (pl)
BR112016016546A2 (pl)
BR112016017103A2 (pl)
BR112016018264A2 (pl)
BR112016017031A2 (pl)
BR112016016924A2 (pl)
BR112016016421A2 (pl)
BR112016016106A2 (pl)
BR112016012568A2 (pl)
BR112016016558A2 (pl)
BR112016015798A2 (pl)
BR112016017960A2 (pl)
BR112016018252A2 (pl)
BR112016017356A2 (pl)
BR112016016468A2 (pl)
BR112016015915A2 (pl)
BR112016003522A2 (pl)
BR112016016459A2 (pl)
BR112016014482A2 (pl)